Pfizer-BioNTech potential COVID vaccine shows promise in second early trial
New York: German biotech BioNTech and U.S. drugmaker Pfizer Inc recently said data from an early-stage trial of their experimental coronavirus vaccine shReutersowed that it prompted an immune response and was well-tolerated, similar to results seen in prior early test.
In the study conducted in Germany on 60 healthy volunteers, the vaccine-induced virus-neutralizing antibodies in those given two doses, in-line with previous results from an early-stage U.S. trial.
Read Also: Pfizer, BioNTech COVID-19 vaccine expected to be ready for approval by 2020 end
BioNtech's U.S. shares rose 5%, while Pfizer's stock was marginally higher at $36.44.
Under expedited development plans, the companies have said they expect to begin a trial later this month with up to 30,000 subjects with the aim of demonstrating the vaccine's efficacy.
A safe and effective vaccine against the novel coronavirus is seen as essential to ending a pandemic that is still raging and has claimed more than 600,000 lives worldwide.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.